Record product revenue of tUSD 5,924 achieved in Q3 2017.
Revenue reached tUSD 22,092 in the first nine months of 2017 representing an increase of 301% compared to the same period last year.
U.S. revenue increased 173% to tUSD 10,943
EU revenue increased 89% to tUSD 2,839
RoW upfront revenues were tUSD 8,250
71% of U.S. transplant centers have utilized Envarsus XR since launch.
Ulf Meier-Kriesche, MD joined the management team as Chief Scientific Officer, bringing substantial clinical transplant experience and senior industry medical affairs experience within transplantation and immunology.
Veloxis (OMX: VELO) reported a net loss of tUSD 8,421 for the first nine months of 2017 compared to a net loss of tUSD 23,961 for the same period in 2016. The reported operating net loss is in line with expectations.
In connection with the financial report, Veloxis's CEO Craig Collard said:
"I am very pleased to see the steady momentum with our lead product Envarsus and believe we will continue to see significant growth. The addition of Ulf Meier-Kriesche has expanded our capabilities in development and he should be instrumental in our business development efforts in the future as we search for both commercial and development opportunities that will compliment Envarsus and add shareholder value."
Outlook for 2017
Veloxis maintains its 2017 outlook of operating loss before the recognition of income from license agreements and before accounting for stock compensation in the range of USD 10 ? 15 million, as noted in the Interim Report for the period 1 January to 30 June 2017.
Conference Call
A conference call will be held tomorrow, 15 November, 2017 at 4:00 PM CET (Denmark); 3:00 PM GMT (London), 10:00 AM EST (New York).
To access the live conference call, please dial one of the following numbers:
Confirmation Code: 4943899
UK: +44(0)20 3427 1907
U.S.: +1 646 254 3362
DK: +4532 71 16 59
Following the conference call, a recording will be available on the Company's website: http://www.veloxis.com.
A complete copy of Veloxis's Interim Report for the First Nine Months of 2017 can be accessed in the Download Center on the Company's website: http://www.veloxis.com/downloadCenter.cfm.
TSX VENTURE COMPANIES
BULLETIN V2024-1200
LEONOVUS INC. ("LTV.WT")BULLETIN TYPE: Warrant Expiry-DelistBULLETIN DATE: April 25, 2024TSX Venture Tier 2 Company
Effective at the opening, May 2, 2024, the Share Purchase Warrants of the Company will...
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....
Dominion Lending Centres Inc. ("DLCG" or the "Corporation") is pleased to announce that it has completed a sale of its 52% interest in Cape Communications International Inc. ("Impact") for aggregate cash proceeds of $3.71 million (the "Purchase...
Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) ("the Company" or "Orbia") today released unaudited results for the first quarter of 2024.
Orbia's first quarter performance reflects the continued weakness in the market environment,...
BDV Solutions, the leading provider of untapped global talent to support the needs of hiring organizations across the U.S. economy, today announced it has acquired Arkansas Global Connect (AGC), a Conway, Arkansas-based company that provides U.S....
The B.C. Securities Commission (BCSC) issued a BC Notice today to raise awareness of a 2023 Commission decision about promotional disclosure, and how it must be presented to comply with the law.
The decision, Re Stock Social Inc., interpreted a...